Literature DB >> 11980654

Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma.

Jörg Wischhusen1, Gundram Jung, Ivan Radovanovic, Christoph Beier, Joachim P Steinbach, Andreas Rimner, Huatao Huang, Jörg B Schulz, Hiroko Ohgaki, Adriano Aguzzi, Hans-Georg Rammensee, Michael Weller.   

Abstract

Interactions of CD70, a tumor necrosis factor-related cell surface ligand and its receptor, CD27, are thought to play an important role for T-, B-, and natural killer-cell activation. However, ligation of CD27 can also induce apoptosis. Human glioblastoma is paradigmatic for cancer-associated immunosuppression. We identified CD70 as a radioinducible gene in U87 MG glioma cells. A screening of a panel of human glioma cell lines revealed that 11 of 12 cell lines expressed CD70 mRNA and protein. Two human neuroblastoma cell lines did not express CD70. CD70 mRNA expression was enhanced by irradiation in 8 of 12 glioma cell lines in a p53-independent manner. No alteration in CD70 expression was observed after glioma cell exposure to cytotoxic drugs such as lomustine. CD70 protein was also detected by immunocytochemistry in 5 of 12 glioblastomas and 3 of 4 anaplastic astrocytomas in vivo. CD27 expression was not detected in any glioma cell line, and there was no evidence for autocrine or backward signaling of the CD70 system in human glioma cells. Unexpectedly, CD70 expressed on glioma cells did not increase the immunogenicity of glioma cells in vitro. In contrast, CD70-positive glioma cells induced apoptosis in peripheral blood mononuclear cells (PBMCs) in a CD70-dependent manner. Neutralization of CD70 expressed on glioma cells prevented apoptosis and enhanced the release of tumor necrosis factor-alpha in cocultures of glioma cells and PBMCs. The effects of CD70-expressing glioma cells on PBMCs were mimicked by agonistic CD27 antibodies. Conversely, the shedding of CD27 by PBMCs was identified as a possible escape mechanism from glioma cell-induced CD70-dependent apoptosis. Thus, induction of B-cell and T-cell apoptosis via interactions of CD70 expressed on glioma cells and CD27 expressed on B and T cells may be a novel way for the immune escape of malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11980654

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  70 in total

1.  CD70 expression patterns in renal cell carcinoma.

Authors:  Lucia B Jilaveanu; Joshua Sznol; Saadia A Aziz; Dylan Duchen; Harriet M Kluger; Robert L Camp
Journal:  Hum Pathol       Date:  2012-03-07       Impact factor: 3.466

Review 2.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 3.  Immunosuppressive mechanisms in glioblastoma.

Authors:  Edjah K Nduom; Michael Weller; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

4.  TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma.

Authors:  Z-Z Yang; D M Grote; B Xiu; S C Ziesmer; T L Price-Troska; L S Hodge; D M Yates; A J Novak; S M Ansell
Journal:  Leukemia       Date:  2014-02-26       Impact factor: 11.528

Review 5.  Engineering challenges for brain tumor immunotherapy.

Authors:  Johnathan G Lyon; Nassir Mokarram; Tarun Saxena; Sheridan L Carroll; Ravi V Bellamkonda
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

6.  CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma.

Authors:  Yuk Pheel Park; Linchun Jin; Katie B Bennett; Dunrui Wang; Kristianna M Fredenburg; Jennifer E Tseng; Lung-Ji Chang; Jianping Huang; Edward K L Chan
Journal:  Oral Oncol       Date:  2018-02-20       Impact factor: 5.337

Review 7.  Overview of cellular immunotherapy for patients with glioblastoma.

Authors:  Elodie Vauleon; Tony Avril; Brigitte Collet; Jean Mosser; Véronique Quillien
Journal:  Clin Dev Immunol       Date:  2010-10-04

8.  Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75.

Authors:  M C Ryan; H Kostner; K A Gordon; S Duniho; M K Sutherland; C Yu; K M Kim; A Nesterova; M Anderson; J A McEarchern; C-L Law; L M Smith
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

9.  Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma.

Authors:  Qiong J Wang; Ken-Ichi Hanada; Paul F Robbins; Yong F Li; James C Yang
Journal:  Cancer Res       Date:  2012-10-15       Impact factor: 12.701

10.  Target proteomic profiling of frozen pancreatic CD24+ adenocarcinoma tissues by immuno-laser capture microdissection and nano-LC-MS/MS.

Authors:  Jianhui Zhu; Song Nie; Jing Wu; David M Lubman
Journal:  J Proteome Res       Date:  2013-05-29       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.